Johnson & Johnson said its pharmaceuticals group plans to file regulatory applications for more than 10 new drugs and seek more than 25 new indications for existing drugs by 2017. Some of the drugs in late-stage development that the firm plans to submit for approval include simeprevir for treatment of hepatitis C, ibrutinib and daratumumab for hematologic malignancies, and sirukumab and guselkumab for treatment of immune-mediated disorders. "We are preparing for the next wave of growth," said Joaquin Duato, worldwide chairman of J&J's pharmaceuticals group.

Full Story:
Fox Business

Related Summaries